Abstract
BackgroundRecombinant human interleukin-2 (rhIL-2, aldesleukin) is Food and Drug Administration approved for the treatment of metastatic melanoma and renal cell carcinoma and has achieved durable response in a subset of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have